|Day Low/High||8.80 / 9.55|
|52 Wk Low/High||27.62 / 50.74|
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Impax Laboratories, Clearside Biomedical and Mylan were among the biotech stock movers in premarket trading Wednesday.
The drug company saw its stock climb 3% Tuesday on news that it can move ahead with generic Copaxone.
Investors in Impax Laboratories Inc saw new options become available this week, for the September 15th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 234 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
It's unclear how much of the hefty $4,500 price pharmacy benefit managers or insurers will agree to pay to keep Auvi-Q free for most patients.
The autoinjector will be free for insured patients and those whose annual income is less than $100,000.
Sangamo Therapeutics, Impax Laboratories and Portola Pharmaceutical are among the premarket movers in biotech.
The drug maker's shares have fallen 6.2% since Wednesday's market open.
The price of EpiPens has surged about 25% annually since 2007.
Health insurance giant Cigna said it will no longer cover Mylan's EpiPen.
Cigna will now encourage patients to use either Impax's or Mylan's generic autoinjector. Impax offers cheaper prices, but can its manufacturing keep up?
Impax Laboratories, Sangamo Therapeutics and Aralez Pharmaceuticals are among the premarket movers in biotech.
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C.
Glancy Prongay & Murray LLP ("GPM") reminds investors of the January 9, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of a class (the "Class") of investors who purchased Impax...
Glancy Prongay & Murray LLP ("GPM") announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Impax Laboratories, Inc.
The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Impax Laboratories, Inc.
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Impax Laboratories, Inc.
On November 10, 2016, a class action lawsuit was filed in the United States District Court for the District of New Jersey against Impax Laboratories, Inc.